Fig. 3: Implementation of PET/CT in the MTb drug development pipeline.
From: PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development
* a radiolabeled (e.g., Fluorine-18 or Carbon-11) biosimilar version of the anti-TB drug will enable PET/CT imaging (non-invasive, longitudinal, quantitative investigations) for in vivo characterization. Figure created using a licensed version of Biorender.com.
